Short Interest in Fidelity Disruptive Medicine ETF (NASDAQ:FMED) Increases By 31.0%

Fidelity Disruptive Medicine ETF (NASDAQ:FMED) was the recipient of a significant growth in short interest during the month of February. As of February 13th, there was short interest totaling 3,548 shares, a growth of 31.0% from the January 29th total of 2,708 shares. Based on an average daily volume of 6,498 shares, the short-interest ratio is currently 0.5 days. Currently, 0.2% of the shares of the stock are short sold. Currently, 0.2% of the shares of the stock are short sold. Based on an average daily volume of 6,498 shares, the short-interest ratio is currently 0.5 days.

Fidelity Disruptive Medicine ETF Trading Down 0.8%

Fidelity Disruptive Medicine ETF stock traded down $0.20 during midday trading on Monday, reaching $26.01. The company’s stock had a trading volume of 4,027 shares, compared to its average volume of 7,313. The business has a 50-day moving average price of $26.85 and a 200-day moving average price of $26.32. The stock has a market cap of $59.82 million, a PE ratio of 41.33 and a beta of 1.00. Fidelity Disruptive Medicine ETF has a 52 week low of $20.69 and a 52 week high of $29.07.

Hedge Funds Weigh In On Fidelity Disruptive Medicine ETF

Hedge funds and other institutional investors have recently made changes to their positions in the stock. Wealth Enhancement Advisory Services LLC lifted its stake in Fidelity Disruptive Medicine ETF by 4.6% in the fourth quarter. Wealth Enhancement Advisory Services LLC now owns 714,991 shares of the company’s stock valued at $19,712,000 after purchasing an additional 31,629 shares during the last quarter. Jane Street Group LLC lifted its position in Fidelity Disruptive Medicine ETF by 95.4% during the fourth quarter. Jane Street Group LLC now owns 91,414 shares of the company’s stock valued at $2,473,000 after purchasing an additional 44,630 shares during the last quarter. BXM Wealth LLC bought a new position in Fidelity Disruptive Medicine ETF in the fourth quarter valued at $243,000. Vise Technologies Inc. bought a new stake in Fidelity Disruptive Medicine ETF during the fourth quarter worth about $234,000. Finally, Virtu Financial LLC purchased a new position in shares of Fidelity Disruptive Medicine ETF in the 4th quarter worth about $228,000.

About Fidelity Disruptive Medicine ETF

The Fidelity Disruptive Medicine ETF (FMED) is an exchange-traded fund that mostly invests in health care equity. The fund is an actively managed fund that invests in companies involved in disruptive innovation in Health Care. The fund invests in securities of domestic and foreign issuers FMED was launched on Apr 16, 2020 and is managed by Fidelity.